Esperion Therapeutics | ESPR - Operating Expenses


Esperion Therapeutics reported $83.21M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Amarin USD 51.48M 113K Dec/2025
Amgen USD 4.78B 1.12B Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Cipla INR 59.27B 1.71B Mar/2026
CSL USD 5.7B 2.82B Dec/2025
Cytokinetics USD 200.58M 4.46M Mar/2026
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Geron USD 52.07M 6.73M Mar/2026
Grifols EUR 1.99B 217.4M Dec/2025
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Moderna USD 1.78B 242M Mar/2026
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Pfizer USD 90.1B 77.19B Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Sanofi EUR 9.31B 1.2B Mar/2026
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
United Therapeutics USD 5.9B 5.1B Mar/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025